Persistent URL of this record https://hdl.handle.net/1887/3769449
Documents
-
- Download
- Full text
- Publisher's Version
- open access
- Full text at publishers site
In Collections
This item can be found in the following collections:
Tapering of disease-modifying antirheumatic drugs: an overview for daily practice
low disease activity, for glucocorticoids and disease-modifying antirheumatic drugs. We review international
guidelines and recommendations, as well as remaining uncertainties, and provide an overview of the current
literature. Three strategies of tapering are discussed: (1) tapering by discontinuation of one of the drugs in combination therapy regimens, (2) tapering by reducing the dose of one of the drugs in combination therapy regimens, and (3) tapering by dose reduction of monotherapy with disease-modifying antirheumatic drugs. We discuss the outcomes and robustness of evidence of trials and observational cohorts, and we give a trajectory for further research and drug tapering in daily practice.
- All authors
- Maassen, J.M.; Ouwerkerk, L. van; Aliaart, C.F.
- Date
- 2021-09-01
- Journal
- The Lancet Rheumatology
- Volume
- 3
- Issue
- 9
- Pages
- 659 - 670